The1st International Collaboration on Neuroendocrine Tumors (ICON), January 2011. The goal of this program was to provide a forum for the collaboration of ideas and...
Howard A. "Skip" Burris, III, MD, chief medical officer and executive director, Drug Development Program, Sarah Cannon Research Institute in Nashville, Tennessee, discusses successful clinical...
Ezra Cohen, MD, Associate Professor of Medicine, University of Chicago, discusses the utility of inhibiting the mammalian target of rapamycin (mTOR) in head and neck...
